癌症相关贫血的治疗策略
本文通过4例患者病例展示癌症相关贫血的常见与复杂临床场景,综述红细胞生成机制,提出先明确病因再选择治疗的方法,总结静脉铁剂安全性与疗效的临床试验数据,比较静脉铁剂与红细胞输注的不良事件率,讨论一线静脉铁剂单药治疗以减少促红细胞生成素使用,并综述抗坏血酸、脯氨酰羟化酶抑制剂等新型疗法的潜力。
要点
- 癌症相关贫血治疗前应先明确病因再选择特定治疗。
- 静脉铁剂单药一线治疗可减少促红细胞生成素使用。
- 抗坏血酸、脯氨酰羟化酶抑制剂等新型疗法具有治疗潜力。
核心结论
- 尽管靶向治疗应用增加,贫血仍是癌症治疗的常见并发症。
- 医生对静脉铁剂和促红细胞生成素安全性的担忧导致许多癌症患者未接受或接受次优贫血治疗。
- 本文提出先识别病因再选择特定治疗的方法,并讨论静脉铁剂单药一线治疗以减少促红细胞生成素使用。
研究设计与样本
- 本文为综述,通过4例患者病例展示癌症相关贫血的常见与复杂临床场景。
主要发现
- 本文总结了 affirming 当前可用静脉铁剂产品治疗癌症相关贫血安全性与疗效的临床试验数据。
- 本文比较了静脉铁剂与红细胞输注相关的不良事件率。
- 本文讨论了促红细胞生成素诱导肿瘤进展的可能机制。
关键数值与推荐
- 本文提出使用常用实验室检查评估常规患者管理中的铁状态。
- 本文讨论一线静脉铁剂单药治疗贫血癌症患者以减少促红细胞生成素需求。
临床怎么用
- 本文描述通过识别贡献原因再选择特定治疗的方法来管理癌症相关贫血。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite increasing use of targeted therapies to treat cancer, anemia remains a common complication of cancer therapy. Physician concerns about the safety of intravenous (IV) iron products and erythropoiesis-stimulating agents (ESAs) have resulted in many patients with cancer receiving no or suboptimal anemia therapy. In this article, we present 4 patient cases that illustrate both common and complex clinical scenarios. We first present a review of erythropoiesis and then describe our approach to cancer-associated anemia by identifying the contributing causes before selecting specific treatments. We summarize clinical trial data affirming the safety and efficacy of currently available IV iron products used to treat cancer-associated anemia and illustrate how we use commonly available laboratory tests to assess iron status during routine patient management. We compare adverse event rates associated with IV iron vs red cell transfusion and discuss using first-line IV iron monotherapy to treat anemic patients with cancer, which decreases the need for ESAs. A possible mechanism behind ESA-induced tumor progression is discussed. Finally, we review the potential of novel therapies such as ascorbic acid, prolyl hydroxylase inhibitors, activin traps, hepcidin, and bone morphogenetic protein antagonists in treating cancer-associated anemia.
引用
- Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020. PMID: 32556170. doi:10.1182/blood.2019004017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。